Home » Bayer Reports Unexpected Fourth-Quarter Loss on Schering Brand Writedown

Bayer Reports Unexpected Fourth-Quarter Loss on Schering Brand Writedown

February 28, 2011

Bayer AG posted its first quarterly loss in seven years on a writedown of the Schering drug brand and said pharmaceutical sales growth isn’t likely to match the market this year.
Bloomberg

09Feb
Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19
10Feb
FDA Under the Biden Administration: What’s to Come and What It Will Mean
11Feb
Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era
17Feb
Effective Auditing for Manufacturing Quality
23Mar
Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges
30Mar
Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Bayer Reports Unexpected Fourth-Quarter Loss on Schering Brand Writedown

Upcoming Events

Maintaining Your Risk-Based Cleaning and Disinfectant Programs: Best Practices During COVID-19

FDA Under the Biden Administration: What’s to Come and What It Will Mean

Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

Effective Auditing for Manufacturing Quality

Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

Data Integrity for GMP/Postmarket Professionals: Core Requirements, Expectations and Challenges

Featured Products

Biological Risk Evaluation and Management for Medical Devices

GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

Desidustat Improves Oxygenation for Hospitalized COVID-19 Patients

Abbott’s Panbio COVID-19 Test Gets Additional CE Marks

FDA Gives MeiraGTx’s Achromatopsia Therapy Fast-Track Status

TGA Investigates COVID-19 Tests and Emerging Variants

The Revised ICH E8: A Guide to New Clinical Trial Requirements